Malignant Tumors Clinical Trial
Official title:
Restricted Calorie Ketogenic Diet as a Treatment in Glioblastoma Multiforme: a Clinical Study
Malignant tumor incidence showed an upgrade trend in recent years. Standard therapy for malignant tumor includes surgery followed by radiation and chemotherapy. Despite optimal treatment the prognosis remains poor. There is an urgent need for more effective therapies. The Warburg effect has been widely observed in human cancers. The main energy supply of tumor cells are aerobic glycolysis. Therefore, they are highly dependent on glucose metabolism. Recently, some scholars have suggested that 'Restricted calorie Ketogenic Diet (RKD)' might be able to inhibit glycolysis and thus anti-tumor by restricting carbohydrate intake. This will 'starve' cancer cells, which will lead to cell death. There are many animal and in vitro studies shown that RKD can reduce the tumor size and thus tumor cell growth of malignant tumors. However, a consistent positive result can not be found within a small sample of clinical trials. In this study, 40 patients with malignant tumors will be treated with or without RKD. The safety and efficacy of RKD and the patients' tolerance will be observed in order to understand whether this therapy can be a potential new treatment This clinical study is comparatively large internationally. It is the first domestically. This study is essential to extend the survival of patients with malignant tumors, and to study clinical nutrition support and its metabolic pathways for malignant tumors.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02041871 -
Interest of PReOPerative Immunonutrition in Liver Surgery for Cancer
|
N/A | |
| Completed |
NCT03110783 -
Bioseal Dural Sealing Study BIOS-14-001
|
Phase 3 | |
| Recruiting |
NCT05516914 -
A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02534506 -
Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT05714748 -
Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors
|
Phase 1 | |
| Recruiting |
NCT05987098 -
BBPA PET/CT in Patients With Malignant Tumors
|
N/A | |
| Not yet recruiting |
NCT01092247 -
The Effect of Ketogenic Diet on Malignant Tumors- Recurrence and Progress
|
N/A | |
| Recruiting |
NCT04702841 -
CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors
|
Early Phase 1 | |
| Completed |
NCT00165100 -
Dynamic Area Telethermometry (DAT) as an Imaging Modality in Patients With Cancer
|
N/A | |
| Suspended |
NCT05615974 -
A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03542773 -
Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET
|
Phase 1 | |
| Completed |
NCT05293990 -
Usefulness of Gadovist-enhanced FLAIR Imaging
|
N/A | |
| Completed |
NCT01509612 -
Additive Homeopathy in Cancer Patients
|
Phase 3 | |
| Completed |
NCT01678690 -
An Exploratory Study of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant Tumors
|
Phase 0 | |
| Suspended |
NCT06270394 -
FAP PET/CT or PET/MR Production in the Diagnosis, Staging, and Efficacy Assessment of Malignant Tumors Application
|
N/A | |
| Completed |
NCT00412503 -
Temozolomide in Association With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents
|
Phase 1 |